Preclinical Evaluation of 177 Lu-rhPSMA-10.1, a Radiopharmaceutical for Prostate Cancer: Biodistribution and Therapeutic Efficacy
Journal of Nuclear Medicine · 2025
DOI: 10.2967/jnumed.124.268508 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Nuclear Medicine, 2025. Verfasst von Caroline Foxton und 6 weiteren Autor:innen. Beteiligte Einrichtung: Blue Earth Diagnostics Ltd., Oxford, United Kingdom; caroline.foxton@blueearthdx.com. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Radiopharmaceuticals, Lutetium, Radioisotopes. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Blue Earth Diagnostics Ltd., Oxford, United Kingdom; caroline.foxton@blueearthdx.com.
- Blue Earth Therapeutics Ltd., Oxford, United Kingdom.
- Minerva Imaging, Ølstykke, Denmark.
- IsoTherapeutics Group LLC, Angleton, Texas; and.
- Department of Oncology, University of Oxford, Oxford, United Kingdom.
Zitieren
APA
Foxton, C., Waldron, B., Veggerby Grønlund, R., Simón, J. J., Cornelissen, B., O'Neill, E., & Stevens, D. (2025). Preclinical Evaluation of 177 Lu-rhPSMA-10.1, a Radiopharmaceutical for Prostate Cancer: Biodistribution and Therapeutic Efficacy. Journal of Nuclear Medicine. https://doi.org/10.2967/jnumed.124.268508
Vancouver
Foxton C, Waldron B, Veggerby Grønlund R, Simón JJ, Cornelissen B, O'Neill E, et al. Preclinical Evaluation of 177 Lu-rhPSMA-10.1, a Radiopharmaceutical for Prostate Cancer: Biodistribution and Therapeutic Efficacy. Journal of Nuclear Medicine. 2025. doi:10.2967/jnumed.124.268508
BibTeX
@article{Foxton2025,
author = {Foxton, Caroline and Waldron, Bradley and Veggerby Grønlund, Rikke and Simón, Jaime Jim and Cornelissen, Bart and O'Neill, Edward and Stevens, Daniel},
title = {Preclinical Evaluation of 177 Lu-rhPSMA-10.1, a Radiopharmaceutical for Prostate Cancer: Biodistribution and Therapeutic Efficacy},
journal = {Journal of Nuclear Medicine},
year = {2025},
doi = {10.2967/jnumed.124.268508}
}
EUVIMED